首页 > 市场调查报告书 > 医疗设备

药物递输设备呼吸器

市场调查报告书

商品编码

1634176

全球雾化器市场 - 2025 - 2033

Global Nebulizer Market - 2025 - 2033

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球雾化器市场规模达到15.7亿美元，预计2033年将达到24.9亿美元，2025-2033年预测期间复合年增长率为5.5%。

雾化器是一种将液体药物转化为细雾的医疗设备，可以直接吸入肺部。这种药物传递技术对于患有气喘、慢性阻塞性肺病 (COPD)、囊性纤维化和其他肺部疾病等呼吸系统疾病的患者非常有用。雾化器以气雾剂形式给药，可以更快地吸收并更有效地治疗呼吸系统疾病。使用雾化器的主要优点之一是它能够成功地将药物输送给可能难以使用常规吸入器的患者，例如幼儿或患有严重呼吸系统疾病的患者。雾化器的雾气使吸入更容易，并且不需要吸入器所需的特殊方法。

对雾化器的需求不断增长是预测期内推动市场的驱动因素。呼吸系统疾病的日益流行增加了对雾化器的需求，因为它们在慢性呼吸系统疾病的治疗和管理中发挥着至关重要的作用。例如，根据美国气喘和过敏基金会的数据，美国有近 2800 万人患有气喘。这相当于大约每十二个人中就有一个。在美国，气喘影响着 18 岁及以上的近 2,300 万人。女性比男性更容易患气喘。气喘影响约 11.0% 的成年女性和 6.8% 的男性。它是青少年的主要慢性疾病。目前，约有 490 万名 18 岁以下儿童患有气喘。

市场动态：

驱动程式和限制

雾化器需求增加

雾化器需求的增加预计将成为全球雾化器市场成长的重要因素。对雾化器的需求不断增加是由于呼吸系统疾病的增加、技术的进步、最近的产品发布和批准。

随着慢性阻塞性肺病、气喘和鼻窦炎等慢性呼吸道疾病在全球范围内变得越来越普遍，雾化器对于有效的医疗管理和重症监护来说是必要的。例如，根据卫生与公共服务部的数据，全球每 20 人就有 1 人患有慢性呼吸道疾病 (CRD)。东亚和南亚的 CRD 死亡率最高。中低和低社会人口指数 (SDI) 国家的 CRD 死亡率年龄标准化率最高。关于慢性呼吸道疾病 (CRD) 的新研究结果显示，它是全球第三大死因，导致全球约 400 万人死亡。这些人中约 60%（约 2.62 亿）被诊断出患有气喘，使其成为最常见的 CRD。自 1990 年以来，CRD 新病例数量增加了 49.0%，这主要是由于人口增长。另一方面，年龄标准化发生率下降了 5.3%。呼吸系统疾病数量的增加增加了对雾化器的需求并推动了市场。

技术进步也对不断增长的需求产生重大影响。雾化器设计的创新，例如振动网雾化器的开发，提高了药物输送效率和患者依从性。现代科技通常比前几代技术更安静、更快、更紧凑，这使得它们对使用者更具吸引力。随着製造商继续在研发上投入资金以带来复杂的功能并改善用户体验，雾化器作为治疗替代品的吸引力肯定会扩大。例如，2024 年 5 月，Medline 推出了 Hudson RCI TurboMist 小容量雾化器，用于呼吸治疗中的给药。 Medline 声称 TurboMist 是市场上速度最快的小容量雾化器，因为它可以在三分钟内输送药物。相比之下，传统雾化器至少需要 10 分钟才能提供治疗。 Medline 开发的 TurboMist 每分钟输送的药物量是典型雾化器的 2.5 倍。

设备成本高

设备成本高等因素预计将阻碍全球雾化器市场。主要问题之一是雾化器的初始成本较高，尤其是网状雾化器等复杂类型。压缩机雾化器的价格从 150 美元到 300 美元不等，而超音波装置的价格通常在 50 美元到 100 美元之间。许多用户，特别是低收入地区或人口统计的用户，由于成本差异而无法购买高品质的雾化器。

有关此报告的更多详细资讯 - 索取样品

A nebulizer is a medical device that converts liquid medication into a fine mist, allowing for direct inhalation into the lungs. This technique of medicine delivery is very useful for patients suffering from respiratory illnesses like asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other pulmonary disorders. Nebulizers, which administer medication in aerosol form, allow for faster absorption and more effective treatment of respiratory disorders. One of the primary advantages of utilizing a nebulizer is its ability to deliver medication successfully to patients who may struggle with regular inhalers, such as small children or those with severe respiratory disorders. A nebulizer's mist makes inhalation easier and eliminates the need for particular methods required by inhalers.

The increasing demand for nebulizers is the driving factor that drives the market over the forecast period. the increasing prevalence of respiratory diseases increases the demand for nebulizers since they play a vital role in the treatment and management of chronic respiratory diseases. For instance, according to the Asthma and Allergy Foundation of America, Nearly 28 million people in the United States suffer with asthma. This equates to around one in every twelve people. Asthma affects almost 23 million persons in the United States, aged 18 and older. Asthma is more frequent in women than men. Asthma affects around 11.0% of female adults and 6.8% of male people. It is a major chronic disease among youngsters. Currently, around 4.9 million children under the age of 18 have asthma.

Market Dynamics: Drivers & Restraints

Increasing demand for nebulizers

The increasing demand for nebulizers is expected to be a significant factor in the growth of the global nebulizer market. The increasing demand for nebulizers is due to an increasing number of respiratory disorders, technological advancements, recent product launches, and approvals.

As chronic respiratory conditions like COPD, asthma, and sinusitis become more prevalent globally, nebulizers are necessary for effective healthcare management and critical care. For instance, according to the Department of Health & Human Services, 1 in 20 people globally suffers from chronic respiratory disease (CRD). East Asia and South Asia had the highest rates of CRD mortality. Low-middle and low Socio-demographic Index (SDI) countries had the highest age-standardized rates of CRD deaths. New findings on chronic respiratory disease (CRD) now show it is the third leading cause of death globally, accounting for approximately 4 million deaths worldwide. Asthma was diagnosed in approximately 60% of these people (approximately 262 million), making it the most common CRD. Since 1990, the number of new cases of CRDs has increased by 49.0%, owing primarily to population growth. The age-standardized incidence rate, on the other hand, has decreased by 5.3%. The increase in the number of respiratory disorders increases the demand for nebulizers and drives the market.

Technological advancements also have a major influence on increasing demand. Innovations in nebulizer design, such as the development of vibrating mesh nebulizers, have increased drug delivery efficiency and patient compliance. Contemporary technologies are frequently quieter, faster, and more compact than older generations, making them more enticing to users. As manufacturers continue to spend in research and development to bring sophisticated features and improve user experience, the attractiveness of nebulizers as a therapeutic alternative will most certainly expand. For instance, in May 2024, Medline has launched the Hudson RCI TurboMist small-volume nebulizer for administering medication in respiratory treatment. Medline claims that TurboMist is the fastest small-volume nebulizer on the market, as it can deliver medication in under three minutes. In contrast, traditional nebulizers can take at least 10 minutes to offer treatment. Medline created TurboMist to deliver 2.5 times more medication per minute than a typical nebulizer.

High costs of devices

Factors such as high costs of devices are expected to hamper the global nebulizer market. One of the primary concerns is the high initial cost of nebulizers, especially complex types like mesh nebulizers. Compressor nebulizers can cost anywhere from $150 to $300, although ultrasonic units are typically priced between $50 and $100. Many users, particularly those in lower-income regions or demographics, cannot manage to buy high-quality nebulizers due to cost disparities.

For more details on this report - Request for Sample

Segment Analysis

The global nebulizer market is segmented based on product type, portability, application, end-user, and region.

Jet nebulizer segment is expected to dominate the global nebulizer market share

The jet nebulizer segment is anticipated to dominate the global nebulizer market owing to its established presence, cost-effectiveness, and widespread acceptance among healthcare providers and patients. The affordable price of jet nebulizers is one of the primary reasons for their popularity. Jet nebulizers are often less expensive than other types of nebulizers, including ultrasonic and mesh nebulizers. This reduction in expenses makes them more accessible to a wider range of patients, especially in low- and middle-income nations where healthcare expenditures are constrained. The ability to provide effective aerosolized medication at lower expenses pushes healthcare facilities to use jet nebulizers as a common treatment option. The price of a basic jet nebulizer starts from $50 which is affordable by many people.

Jet nebulizers have an extended track record of being reliable and successful at delivering drugs. They are frequently used in hospitals and home care settings, so they are known to both healthcare providers and patients. Jet nebulizers are easy to use, allowing for effective control of respiratory disorders without the need for professional training for patients or caregivers. This familiarity adds to the sustained preference for jet nebulizers over the latest innovations, which may necessitate changes in usage patterns. The jet nebulizer maintains its dominance due to its affordability, dependability, and effectiveness in treating respiratory disorders.

Geographical Analysis

North America is expected to hold a significant position in the global nebulizer market share

The dominance of the North American market in the global nebulizer market is due to various factors such as advanced healthcare infrastructure, high prevalence of respiratory diseases, product launches, and approvals, and increasing adoption of nebulizers.

The increasing prevalence of respiratory disorders in this region increases the demand for nebulizers. For instance, according to health.gov, respiratory diseases affect millions of people in the United States. More than 25 million people in the United States have asthma. Strategies to reduce environmental triggers and make sure people get the right medications can help prevent hospital visits for asthma. In addition, more than 16 million people in the United States have COPD (chronic obstructive pulmonary disease), which is a major cause of death.

Furthermore, North America's well-established healthcare system contributes significantly to the nebulizer market. The region offers a large number of healthcare institutions equipped with the latest medical technologies, making nebulizers easily accessible to patients.

Asia Pacific is growing at the fastest pace in the global nebulizer market

The Asia Pacific region is emerging as the fastest-growing market for anesthesia and respiratory devices, owing to a combination of demographic trends, increased healthcare investment, and an increasing prevalence of respiratory diseases.

The increasing prevalence of respiratory diseases is one of the factors that drive the market in this region. For instance, according to The International Primary Care Respiratory Group, India has one of the highest rates of chronic respiratory illness. India accounts for 15.69% of worldwide chronic respiratory diseases, whereas 30.28% of all global deaths from chronic respiratory diseases occur in India. India has the world's greatest number of COPD (Chronic Obstructive Pulmonary Disease) cases, totaling 55.23 million. India has the second-highest number of COPD-related deaths globally, accounting for almost 0.85 million.

Competitive Landscape

The major global players in the global nebulizer market OMRON Healthcare, GE Healthcare, Koninklijke Philips N.V., Allied Medical LLC, Vectura Group Ltd, PARI Respiratory Equipment, Inc., Aerogen, Drive Devilbiss International, Briggs Healthcare, Beurer GmBH among others.

Emerging Players

Dr Morepen, Everycom Electronics, and Niscomed among others

Key Developments

In January 2023, Synergy Life Science developed Nebi, a portable, battery-operated nebulizer for various applications, making it the first of its kind in the consumer health and wellness market.
In November 2024, Students from the University of Karachi developed the world's smallest rechargeable nebulizer, an innovative device designed to offer convenience and ease of use for patients during travel or at the office. The nebulizer can operate continuously for 35 minutes and, once fully charged, remains functional for up to two days. This makes it a reliable and convenient option for individuals requiring frequent nebulization.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global nebulizer market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Portability
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.2. Increasing Demand for Nebulizers
- 4.1.3. Restraints
- 4.1.4. Limitations Associated with Nebulizers
- 4.1.5. Opportunity
- 4.1.6. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 6.1.2. Market Attractiveness Index, By Type
6.2. Jet Nebulizer*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Ultrasonic Nebulizer
6.4. Mesh Nebulizer

7. By Portability

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
- 7.1.2. Market Attractiveness Index, By Portability
7.2. Tabletop Nebulizer*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Portable Nebulizer

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. COPD*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Asthma
8.4. Others

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Service Centres
9.4. Homecare

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. The U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. UK
  - 10.3.7.3. France
  - 10.3.7.4. Italy
  - 10.3.7.5. Spain
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. OMRON Healthcare*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. GE Healthcare
12.3. Koninklijke Philips N.V.
12.4. Allied Medical LLC
12.5. Vectura Group Ltd
12.6. PARI Respiratory Equipment, Inc.
12.7. Aerogen
12.8. Drive Devilbiss International
12.9. Briggs Healthcare
12.10. Beurer GmBH

LIST NOT EXHAUSTIVE